Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ertugliflozin in Chronic Heart Failure
Sponsor: Yale University
Summary
The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy. There are two general purposes for this study. The proposed study is both larger and more rigorous than essentially all PK/PD studies that form the basis of current practice with loop diuretics as well as all studies looking at add-on thiazide therapy (current guideline-recommended adjuvant). The second is to generate a mechanistic understanding of the pleotropic cardio-renal factors with chronic therapy that differentiate ertugliflozin from traditional diuretics particularly in how they maintain reduced blood volume without the complication of over-diuresis and volume depletion.
Official title: Ertugliflozin in Chronic Heart Failure: Cardio-renal and Diuretic Effects
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2021-03-10
Completion Date
2025-12-30
Last Updated
2025-10-08
Healthy Volunteers
No
Conditions
Interventions
Ertugliflozin
Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Metolazone
Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Placebo
Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Locations (1)
Yale School of Medicine
New Haven, Connecticut, United States